Sakar Healthcare Q2 FY27: PAT ₹1,028 Cr & Rev ₹7,297 Cr

Metric	Value
Revenue	₹7,297 Cr
Net Profit (PAT)	₹1,028 Cr

📢 Key Event
Sakar Healthcare reported Q1FY27 consolidated revenue of ₹7,297 crores, up 38% YoY, with PAT rising 120% to ₹1,028 crores.

🔄 What Changed
Revenue grew 38% YoY to ₹7,297 crores; PAT increased 120% YoY to ₹1,028 crores; EBITDA margin expanded to 29% from 24%; Gross profit margin improved to 53% from 45%.

🔮 What's Next
The company expects converting regulatory approvals into commercial launches and supplies to improve capacity utilization and operating leverage, targeting sustainable growth through its oncology platform expansion.

💡 Investor Takeaway
Strong revenue and PAT growth driven by oncology momentum and regulatory progress position Sakar Healthcare for scalable, profitable expansion in global oncology markets.

Sakar Healthcare reported consolidated revenue of ₹7,297 crores for Q1FY27, up 38% YoY, driven by oncology product launches and export growth. Gross profit rose 61% to ₹3,839 crores with a 53% margin, while PAT surged 120% to ₹1,028 crores, expanding to 14% margin. EBITDA increased 67% YoY to ₹2,125 crores with a 29% margin, reflecting strong operating leverage and cost discipline. The company highlighted 65 new oncology contracts, 16 marketing authorizations, and 33 technology transfers as key growth enablers, positioning it for sustained profitability and market expansion in regulated oncology markets.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SAKAR ✨ Ask AI About This

About Sakar Healthcare Limited (SAKAR)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,550.15 Cr P/E: 102.3

View full SAKAR stock details →

📡 Get AI alerts when SAKAR files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SAKAR — Free

💡 Ask AI about this filing

"How does Sakar Healthcare's oncology pipeline valuation compare to peers?" "What is the expected timeline for commercializing the 16 pending marketing authorizations?" "What is the projected revenue contribution from EU expansion by FY28?"

Ask AI Free →

📊 More SAKAR filings

See all SAKAR filings →

🔥 Also filed on 24 July 2026

CGPOWER CG Power and Industrial Solutions Limited Financial Results OMAXAUTO Omax Autos Limited Financial Results NITCO Nitco Limited Corporate Action LENSKART Lenskart Solutions Limited Annual Report ALLDIGI Alldigi Tech Limited Financial Results RKFORGE Ramkrishna Forgings Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SAKAR files new disclosures

Track SAKAR filings, board meetings, and corporate actions. Free email alerts at 5 PM.